This dosage information may not include all the information needed to use Cladribine safely and effectively. See additional information for Cladribine.
The information at Drugs.com is not a substitute for medical advice. ALWAYS consult your doctor or pharmacist.
Usual Adult Dose for Hairy Cell Leukemia
0.09 mg/kg/day by continuous IV infusion for 7 days.
Consider delaying or discontinuing the drug if neurotoxicity or renal toxicity occurs. The risk of opportunistic infection is significant, particularly in cases of cladribine-induced febrile neutropenia.
Prior to and during cladribine therapy, prophylaxis against hyperuricemia with allopurinol is recommended. Careful monitoring of body temperature, complete blood cell counts, serum electrolytes, BUN, and creatinine concentrations for at least 4-8 weeks is recommended. Profound bone marrow suppression should be expected within the first 2 weeks of therapy. Red blood cell transfusions are required in 44% of patients. Platelet transfusions are required in 14% of patients. Platelet, leukocyte, and erythrocyte counts tend to recover by day 12, week 5, and week 8, respectively.